Please use this identifier to cite or link to this item: https://doi.org/10.3945/ajcn.2009.29121
DC FieldValue
dc.titleEffect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: A randomized, double-blind, controlled trial
dc.contributor.authorDangour, A.D
dc.contributor.authorAllen, E
dc.contributor.authorElbourne, D
dc.contributor.authorFasey, N
dc.contributor.authorFletcher, A.E
dc.contributor.authorHardy, P
dc.contributor.authorHolder, G.E
dc.contributor.authorKnight, R
dc.contributor.authorLetley, L
dc.contributor.authorRichards, M
dc.contributor.authorUauy, R
dc.date.accessioned2020-10-27T06:49:33Z
dc.date.available2020-10-27T06:49:33Z
dc.date.issued2010
dc.identifier.citationDangour, A.D, Allen, E, Elbourne, D, Fasey, N, Fletcher, A.E, Hardy, P, Holder, G.E, Knight, R, Letley, L, Richards, M, Uauy, R (2010). Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: A randomized, double-blind, controlled trial. American Journal of Clinical Nutrition 91 (6) : 1725-1732. ScholarBank@NUS Repository. https://doi.org/10.3945/ajcn.2009.29121
dc.identifier.issn0002-9165
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/180989
dc.description.abstractBackground: Increased consumption of n-3 (omega-3) long-chain polyunsaturated fatty acids (LC PUFAs), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may maintain cognitive function in later life. Objective: We tested the hypothesis that n-3 LC PUFA supplementation would benefit cognitive function in cognitively healthy older people. Design: At total of 867 cognitively healthy adults, aged 70-79 y, from 20 general practices in England and Wales were randomly assigned into a double-blind controlled trial of daily capsules providing 200 mg EPA plus 500 mg DHA or olive oil for 24 mo. Treatment-allocation codes were obtained from a central computerized randomization service. Trained research nurses administered a battery of cognitive tests, including the primary outcome, the California Verbal Learning Test (CVLT), at baseline and 24 mo. Intention-to-treat analysis of covariance, with adjustment for baseline cognitive scores, age, sex, and age at leaving full-time education, included 748 (86%) individuals who completed the study. Results: The mean age of participants was 75 y; 55% of the participants were men. Withdrawals and deaths were similar in active (n = 49 and n = 9, respectively) and placebo (n = 53 and n = 8, respectively) arms. Mean (±SD) serum EPA and DHA concentrations were significantly higher in the active arm than in the placebo arm at 24 mo (49.9 ± 2.7 mg EPA/L in the active arm compared with 39.1 ± 3.1 mg EPA/L in the placebo arm; 95.6 ± 3.1 mg DHA/L in the active arm compared with 70.7 ± 2.9 mg DHA/L in the placebo arm). There was no change in cognitive function scores over 24 mo, and intention-to-treat analysis showed no significant differences between trial arms at 24 mo in the CVLT or any secondary cognitive outcome. Conclusions: Cognitive function did not decline in either study arm over 24 mo. The lack of decline in the control arm and the relatively short intervention period may have limited our ability to detect any potential beneficial effect of fish oil on cognitive function in this study. The Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) Study was registered at www.controlled- trials.com as ISRCTN 72331636. © 2010 American Society for Nutrition.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subjectdocosahexaenoic acid
dc.subjecticosapentaenoic acid
dc.subjectolive oil
dc.subjectomega 3 fatty acid
dc.subjectpolyunsaturated fatty acid
dc.subjectage distribution
dc.subjectaged
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcognition
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdeath
dc.subjectdiet supplementation
dc.subjectdouble blind procedure
dc.subjecteducation
dc.subjectfemale
dc.subjectgeneral practice
dc.subjecthuman
dc.subjectlearning
dc.subjectmale
dc.subjectnormal human
dc.subjectoutcome assessment
dc.subjectrandomized controlled trial
dc.subjectscoring system
dc.subjectsex difference
dc.subjectsex ratio
dc.subjectspatial memory
dc.subjectUnited Kingdom
dc.subjectAged
dc.subjectCognition
dc.subjectDietary Supplements
dc.subjectDouble-Blind Method
dc.subjectFatty Acids, Omega-3
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectNeuropsychological Tests
dc.subjectPatient Compliance
dc.typeArticle
dc.contributor.departmentOPHTHALMOLOGY
dc.description.doi10.3945/ajcn.2009.29121
dc.description.sourcetitleAmerican Journal of Clinical Nutrition
dc.description.volume91
dc.description.issue6
dc.description.page1725-1732
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3945_ajcn_2009_29121.pdf157.45 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons